Results 191 to 200 of about 1,868 (233)

Abstract 4145249: THE TWO-HIT HYPOTHESIS?: NEW ONEST SEVERE CARDIOMYOPATHY AND CARDIAC ARRYTHMIA IN A HIGH RISK PATIENT WITH NEUROGENIC ORTHOSTATIC HYPOTENSION ON DROXIDOPA

Circulation
Introduction: Droxidopa (DD) is the second FDA approved drug after midodrine for neurogenic orthostatic hypotension (nOH). Isaacon et al reported that 19 (5.4%) of total 350 patients on droxidopa had 25 cardiac events, most commonly atrial ...
Y. N. Htay, Varun Victor, Lakshmi Murugesan, Thi Ri, Dilanthy R. Annappah, Billal Sikandar, Ataul Qureshi, Ryan Koene   +7 more
semanticscholar   +1 more source

Simultaneous determination of droxidopa and carbidopa by carbon paste electrode functionalized with NiFe2O4 nanoparticle and 2-(4-ferrocenyl-[1,2,3]triazol-1-yl)-1-(naphthalen-2-yl) ethanone

Measurement: Journal of the International Measurement Confederation, 2020
Sayed Zia Mohammadi, Hadi Beitollahi, Massoud Kaykhaii   +2 more
exaly   +2 more sources

Use of Droxidopa to Treat Orthostatic Hypotension in a Patient With Hfref

Journal of Cardiac Failure, 2020
Background Orthostatic hypotension in patients with a low ejection fraction has been associated with a very high morbidity and mortality. Some of this is due to co-morbidity and some is due to the inability to use conventional medications such as ACE inhibitors, ARBs, sacubitril/valsartan and beta blockers because of worsening hypotension.
Sandra B. Charlton, Frank McGrew, Brian Dragutsky   +2 more
openaire   +2 more sources

Droxidopa for Vasopressor Weaning in Critically Ill Patients with Persistent Hypotension: A Multicenter, Retrospective, Single-Arm Observational Study

Journal of Intensive Care Medicine
Background Persistent vasopressor requirements are a common reason for delayed liberation from the intensive care unit (ICU) and adjunct oral agents are sometimes used to hasten time to vasopressor discontinuation.
Andrew J. Webb, Gianna Lh Casal, Kelly A. Newman, Justin R Culshaw, Kalynn A. Northam, Edmond Solomon, Sarah M Beargie, Riley Johnson, Natasha D Lopez, Bryan D Hayes, Russel J Roberts   +10 more
semanticscholar   +1 more source

Droxidopa for Symptomatic Neurogenic Hypotension

Cardiology in Review, 2017
Droxidopa is a first-in-class, orally available, synthetic amino acid precursor of norepinephrine that received accelerated Food and Drug Administration approval in February 2014 after Orphan Drug status for a debilitating condition known as symptomatic neurogenic orthostatic hypotension.
openaire   +3 more sources

Simultaneous determination of droxidopa and carbidopa using a carbon nanotubes paste electrode

Sensors and Actuators B: Chemical, 2013
Abstract A novel carbon paste electrode modified with carbon nanotube and 5-amino-2’-ethyl -biphenyl-2-ol (5AEB) was fabricated. The electrochemical study of the modified electrode, as well as its efficiency for electrocatalytic oxidation of droxidopa and carbidopa, is described. Cyclic voltammetry was used to investigate the redox properties of this
Somayeh Tajik, Somayeh Tajik, M Cepeda
exaly   +3 more sources

The effect of ultrasonic irradiation on the morphology of NiO/Co3O4 nanocomposite and its application to the simultaneous electrochemical determination of droxidopa and carbidopa

Ultrasonics Sonochemistry, 2019
Mohammad Mehdi Foroughi, Shohreh Jahani, Maryam Kazemipour   +2 more
exaly   +2 more sources

Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases

Expert Opinion on Pharmacotherapy, 2019
L-threo-3,4-dihydroxyphenylserine (droxidopa), a pro-drug metabolized to norepinephrine in nerve endings and other tissues, has been commercially available in Japan since 1989 for treating orthostatic hypotension symptoms in Parkinson's disease (PD) patients with a Hoehn & Yahr stage III rating, as well as patients with Multiple System Atrophy (MSA ...
Santiago Pérez-Lloret, Cecilia Quarracino, Matilde Otero-Losada, Olivier Rascol   +3 more
openaire   +4 more sources

Droxidopa approved for neurogenic orthostatic hypotension

American Journal of Health-System Pharmacy, 2014
Droxidopa, a synthetic amino acid precursor of norepinephrine, has been approved as oral therapy for the treatment of neurogenic orthostatic hypotension, FDA and Chelsea Therapeutics announced on February 18.
openaire   +2 more sources

Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension

Clinical Autonomic Research, 2016
Droxidopa has been approved for the treatment of neurogenic orthostatic hypotension (NOH) under the US Food and Drug Administration accelerated approval program, which warrants confirmatory evidence on long-term efficacy of droxidopa. Hereby, we synthesize evidence from published randomized controlled trials (RCTs) about the safety and efficacy of ...
Ahmed Negida, Ahmed Elgebaly, Mohamed Gadelkarim   +2 more
exaly   +4 more sources